Moreover, the real-life data about the probability of stopping the SCIg option are not available

Moreover, the real-life data about the probability of stopping the SCIg option are not available. treat chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. CIDP individuals generally receive hospital-based IV immunoglobulin G (IVIg), and the HS3ST1 switch to SCIg has not yet been systematically proposed. The administration process is the same for PID and CIDP individuals [2]. However, for CIDP individuals, SCIg is definitely indicated only as maintenance treatment after IVIg stabilization. For CIDP individuals, SCIg is considered to lead to similar clinical results than IVIg and is well tolerated [3, 4]. SCIg is also often favored by individuals over IVIg, as it is definitely HO-3867 connected to better satisfaction and quality of life [5C7]. Previous studies have shown than SCIg has the potential to be cost-effective in different countries for both PID individuals [8C14] and CIDP individuals [15C17]. The findings are sensitive to the national context, and more importantly, the cost of individuals teaching and follow-up is definitely often overlooked. Indeed, in the long-term use of SCIg, experts stay responsible for optimal safety, performance and proper medication adherence. Consequently, an interprofessional drug therapy management programme has been proposed for years by the Center for Primary Care and Public Health (Unisant, Lausanne) to train individuals with SCIg and make sure a long-term support programme to them [18, 19]. The aim of this study is definitely to compare the cost of hospital-based IVIg and home-based SCIg associated with the individual support programme (Fig 1) to determine whether this alternate should be advertised in the Swiss context. The model and findings are transposable to additional contexts adopting national unit costs. Open in a separate windows Fig 1 Decision tree for management of CIDP individuals, stable in the chronic phase, treated by IgG infusions.a Interprofessional drug therapy management programme while developed and implemented at the Community Pharmacy of the Center for Primary Care and Public Health (Unisant), University or college of Lausanne, Switzerland. b Duration included transport and time spent at individuals home. c Duration included transport ant time spent at hospital (infusions + waiting time + administrative time). 2. Materials and methods 2.1 Study design SCIg is indicated for CIDP individuals as maintenance therapy after stabilization with IVIg. All individuals started IVIg treatment at the hospital. Resources related to the stabilization phase were not estimated with this study because there is no option management treatment. The study assumed a standard CIDP individual in the chronic phase who was eligible for SCIg (after stabilization). The following two management strategies were compared (Fig 1): Hospital-based IVIg therapy (named IVIg) corresponding to the Lausanne University or college hospital outpatient establishing (CHUV, Lausanne, Switzerland), Home-based SCIg therapy (named SCIg) associated with an interprofessional drug therapy management programme during the initial phase (involving training sessions) and maintenance phase (follow-up). Both strategies were considered to provide identical performance in the treatment of CIDP in terms of relapse rates [3, 20]. We assessed the cost of the strategies over HO-3867 a 48-week period based on the main medical study related to SCIg for CIDP individuals [3, 4, 21] through a cost-minimization analysis. We used a societal perspective, i.e., we regarded as all costs distinguishing the payers (healthcare insurers, individuals, and community). As no data from actual individuals were available, we used a simulation model whose data were primarily based on product monographs, international recommendations and expert opinions. 2.2 Source use and costs The guidelines considered are HO-3867 shown in Table 1. The results were indicated in Swiss francs (CHF) (1 CHF.